top of page

Publications

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states

Drug Alcohol Depend. 2022. DOI: 0.1016/j.drugalcdep.2022.109518.

Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR.

Description and Evaluation of a Pilot Advanced Pharmacy Practice Experience in Addiction Medicine

Am J Pharm Educ. 2022. DOI: 10.5688/ajpe8926

Loera LJ, Hill LG, Zagorski CM, Jermain ML, Tirado CF.

Increasingly powerful opioid antagonists are not necessary

Int J Drug Policy. 2022. DOI: 10.1016/j.drugpo.2021.103457.

Hill LG, Zagorski CM, Loera LJ.

Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review.

Subst Abus. 2022. DOI: 10.1080/08897077.2021.2010161

White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ.

Naloxone counseling for harm reduction and patient engagement

Fam Med. 2017. PMID: 29045991

Han JK, Hill LG, Koenig ME, Das N.

Operation Naloxone: Overdose prevention service learning for student pharmacists

Curr Pharm Teach Learn.  2018. DOI: 10.1016/j.cptl.2018.07.010

Hill LG, Sanchez JP, Laguado SA, Lawson KA.

Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas

JAMA. 2018. DOI: 10.1001/jama.2018.15892

Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. 

State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility

JAMA Intern Med. 2019. DOI: 10.1001/jamainternmed.2019.3653

Hill LG, Reveles KR, Evoy KE. 

Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction

J Am Pharm Assoc. 2019. DOI: 10.1016/j.japh.2019.06.019

Hill LG, Evoy KE, Reveles KR. 

Guidance for male mentors to support the safety and success of female mentees

Am J Pharm Educ. 2019. DOI: 10.5688/ajpe7533

Hill LG, Laguado SA.

bottom of page